21670382Callahan A, Amarenco P, Goldstein LB, Sillesen H, Messig M, Samsa GP, Altafullah I, Ledbetter LY, MacLeod MJ, Scott R, Hennerici M, Zivin JA, Welch KM, SPARCL InvestigatorsArchives of neurologyCholesterol; Diabetes Mellitus, Type 2; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Metabolic Syndrome; Pyrroles; StrokeAdult; Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Physiological Phenomena; Confidence Intervals; Female; Humans; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Proportional Hazards Models; Retrospective Studies; Risk Factors; Triglycerides; Young AdultRisk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Arch Neurol. 2011 Oct; 68(10):1245-51.Arch Neurol2011-06-13T00:00:002011Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.prns:fullNamefull nameprns:hasAuthorListauthor listprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:hasSubjectAreaMajorTopicListhas major subject area listprns:hasSubjectAreaMinorTopicListhas minor subject area listprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed Identifiervivo:authorRankauthor rank in publicationAuthorshipDepartmentvivo:hasSubjectAreahas subject areaInformation Resourcevivo:informationResourceInAuthorshipauthorsvivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcePositionvivo:positionInOrganizationposition in organizationrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonD000369Living Beings93664810.461294Aged, 80 and overD000368Living Beings1341183530.294764AgedD000328Living Beings1578255770.254432AdultD002546Disorders461810.868138Ischemic Attack, TransientD002784Chemicals & Drugs1203560.84156CholesterolD003924Disorders21613720.492443Diabetes Mellitus, Type 2D006538Chemicals & Drugs13720.958765Heptanoic AcidsD008077Chemicals & Drugs29830.964501Lipoproteins, LDLD008875Concepts & IdeasLiving Beings1473249570.258811Middle AgedD005260Physiology1992444050.191167FemaleD012307Concepts & Ideas94153970.464223Risk FactorsD006801Living Beings2262862810.130052HumansD014280Chemicals & Drugs862320.928876TriglyceridesD008297Physiology1931408600.201617MaleD016016Concepts & Ideas3048570.817586Proportional Hazards ModelsD024821Disorders731410.872022Metabolic SyndromeD019161Chemicals & Drugs893780.727233Hydroxymethylglutaryl-CoA Reductase InhibitorsD011758Chemicals & Drugs621840.890788PyrrolesD016001Concepts & Ideas1482280.949739Confidence IntervalsD020521Disorders1609590.510301StrokeD002320Physiology32360.976614Cardiovascular Physiological PhenomenaD008075Chemicals & Drugs32960.948044Lipoproteins, HDLD012189Concepts & Ideas114884310.376516Retrospective StudiesD055815Living Beings97159610.423207Young AdultUniversity of ChicagoLarryGoldsteinLarry Goldstein41.78927490000000-87.601250000000001509Goldstein, Larrytrue1Authorship 5924730.1030110.1030111authors10.2524has subject area